CAM
TXG icon

Cresset Asset Management’s 10x Genomics TXG Stock Holding History

Cresset Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$851K Sell
22,206
-1,270
-5% -$33.3K ﹤0.01% 974
2026
Q1 		$498K Buy
23,476
+4,107
+21% +$82.1K ﹤0.01% 1070
2025
Q4 		$316K Sell
19,369
-4,260
-18% -$64.4K ﹤0.01% 1269
2025
Q3 		$276K Buy
23,629
+877
+4% +$11.4K ﹤0.01% 1280
2025
Q2 		$263K Sell
22,752
-17,699
-44% -$161K ﹤0.01% 1189
2025
Q1 		$353K Sell
40,451
-1,168
-3% -$14.7K ﹤0.01% 1234
2024
Q4 		$598K Sell
41,619
-95,302
-70% -$1.5M ﹤0.01% 1002
2024
Q3 		$3.09M Buy
136,921
+60,774
+80% +$1.26M 0.01% 612
2024
Q2 		$1.48M Buy
76,147
+17,543
+30% +$459K 0.01% 872
2024
Q1 		$2.2M Sell
58,604
-2,398
-4% -$105K 0.01% 601
2023
Q4 		$3.41M Buy
61,002
+10,125
+20% +$441K 0.02% 414
2023
Q3 		$2.1M Sell
50,877
-4,502
-8% -$234K 0.01% 538
2023
Q2 		$3.09M Buy
+55,379
New +$3M ﹤0.01% 523
2021
Q4 		– Sell
-4,058
Closed -$590K – 1298
2021
Q3 		$590K Sell
4,058
-657
-14% -$113K 0.01% 560
2021
Q2 		$924K Sell
4,715
-1,089
-19% -$197K 0.01% 381
2021
Q1 		$1.05M Buy
+5,804
New +$1M 0.02% 289

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cresset Asset Management's TXG Position: Q2 2026 in Review

Cresset Asset Management reduced its 10x Genomics (TXG) stake by 5.4% in Q2 2026, selling an estimated $33.3K and leaving 22,206 shares worth $851K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Cresset Asset Management first reported a position in TXG in Q1 2021 and has held it in 16 quarters since. The position peaked at $3.41M in Q4 2023. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Cresset Asset Management held 22,206 shares of 10x Genomics worth $851K as of Q2 2026.
  • Cresset Asset Management sold 1,270 10x Genomics shares in Q2 2026, an estimated $33.3K.
  • 10x Genomics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #974 holding.
  • Cresset Asset Management first reported a position in 10x Genomics in Q1 2021 and has held it in 16 quarters since.
  • Cresset Asset Management's 10x Genomics position peaked at $3.41M in Q4 2023.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.